West Pharmaceutical Services, Inc. (NYSE: WST) Stock Competitors & Peer Comparison
See WST's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for WST and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| WST | $399.81 | +1.87% | 27.9B | 43.48 | $9.20 | +0.22% |
| ISRG | $452.80 | -3.36% | 160B | 47.07 | $9.62 | N/A |
| BDX | $211.88 | -0.78% | 57.7B | 16.30 | $13.00 | +1.88% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +1.88% |
| MDLN | $39.64 | -0.30% | 34.8B | 29.06 | $1.36 | N/A |
| RMD | $235.30 | -1.68% | 33.1B | 20.40 | $11.53 | +1.06% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.38 | +3.67% | 15.4B | 12.73 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.88% |
| BAX | $25.79 | +0.55% | 13.3B | 12.39 | $2.08 | +0.16% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
WST vs ISRG Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ISRG has a market cap of 160B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ISRG trades at $452.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ISRG's P/E ratio is 47.07. In terms of profitability, WST's ROE is +0.21%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, WST is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for WST.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
WST vs BDX Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, BDX has a market cap of 57.7B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while BDX trades at $211.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas BDX's P/E ratio is 16.30. In terms of profitability, WST's ROE is +0.21%, compared to BDX's ROE of +0.04%. Regarding short-term risk, WST is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
WST vs BDXA Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas BDXA's P/E ratio is 45.70. In terms of profitability, WST's ROE is +0.21%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for WST.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
WST vs MDLN Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, MDLN has a market cap of 34.8B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while MDLN trades at $39.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas MDLN's P/E ratio is 29.06. In terms of profitability, WST's ROE is +0.21%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, WST is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for WST.Check MDLN's competition here
ResMed Inc. (NYSE: RMD)
WST vs RMD Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, RMD has a market cap of 33.1B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while RMD trades at $235.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas RMD's P/E ratio is 20.40. In terms of profitability, WST's ROE is +0.21%, compared to RMD's ROE of +0.25%. Regarding short-term risk, WST is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for WST.Check RMD's competition here
Hologic, Inc. (NASDAQ: HOLX)
WST vs HOLX Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas HOLX's P/E ratio is 31.54. In terms of profitability, WST's ROE is +0.21%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, WST is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for WST.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
WST vs SOLV Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, SOLV has a market cap of 15.4B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while SOLV trades at $90.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas SOLV's P/E ratio is 12.73. In terms of profitability, WST's ROE is +0.21%, compared to SOLV's ROE of +0.03%. Regarding short-term risk, WST is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for WST.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
WST vs BDXB Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas BDXB's P/E ratio is 7.60. In terms of profitability, WST's ROE is +0.21%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, WST is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
WST vs BAX Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, BAX has a market cap of 13.3B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while BAX trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas BAX's P/E ratio is 12.39. In terms of profitability, WST's ROE is +0.21%, compared to BAX's ROE of -0.12%. Regarding short-term risk, WST is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for WST.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
WST vs COO Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, COO has a market cap of 11.9B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while COO trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas COO's P/E ratio is 13.67. In terms of profitability, WST's ROE is +0.21%, compared to COO's ROE of +0.07%. Regarding short-term risk, WST is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for WST.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
WST vs RGEN Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, RGEN has a market cap of 11.1B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while RGEN trades at $173.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas RGEN's P/E ratio is 96.38. In terms of profitability, WST's ROE is +0.21%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, WST is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for WST.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
WST vs AVTR Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, AVTR has a market cap of 10.5B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while AVTR trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas AVTR's P/E ratio is 18.19. In terms of profitability, WST's ROE is +0.21%, compared to AVTR's ROE of +0.06%. Regarding short-term risk, WST is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for WST.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
WST vs ATR Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ATR has a market cap of 9B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ATR trades at $142.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ATR's P/E ratio is 24.92. In terms of profitability, WST's ROE is +0.21%, compared to ATR's ROE of +0.10%. Regarding short-term risk, WST is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
WST vs BLCO Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, BLCO has a market cap of 7.1B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while BLCO trades at $19.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas BLCO's P/E ratio is 30.72. In terms of profitability, WST's ROE is +0.21%, compared to BLCO's ROE of -0.02%. Regarding short-term risk, WST is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for WST.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
WST vs TFX Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, TFX has a market cap of 6.4B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while TFX trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas TFX's P/E ratio is 17.22. In terms of profitability, WST's ROE is +0.21%, compared to TFX's ROE of +0.10%. Regarding short-term risk, WST is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for WST.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
WST vs MMSI Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while MMSI trades at $87.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas MMSI's P/E ratio is 22.30. In terms of profitability, WST's ROE is +0.21%, compared to MMSI's ROE of +0.10%. Regarding short-term risk, WST is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for WST.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
WST vs ICUI Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ICUI has a market cap of 4.3B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ICUI trades at $172.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ICUI's P/E ratio is 21.53. In terms of profitability, WST's ROE is +0.21%, compared to ICUI's ROE of +0.03%. Regarding short-term risk, WST is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for WST.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
WST vs NVST Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, NVST has a market cap of 4B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while NVST trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas NVST's P/E ratio is 17.13. In terms of profitability, WST's ROE is +0.21%, compared to NVST's ROE of +0.21%. Regarding short-term risk, WST is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for WST.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
WST vs PLSE Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while PLSE trades at $53.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas PLSE's P/E ratio is -45.08. In terms of profitability, WST's ROE is +0.21%, compared to PLSE's ROE of -0.78%. Regarding short-term risk, WST is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for WST.Check PLSE's competition here
Stevanato Group S.p.A. (NYSE: STVN)
WST vs STVN Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while STVN trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas STVN's P/E ratio is 20.50. In terms of profitability, WST's ROE is +0.21%, compared to STVN's ROE of +0.09%. Regarding short-term risk, WST is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for WST.Check STVN's competition here
AtriCure, Inc. (NASDAQ: ATRC)
WST vs ATRC Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ATRC has a market cap of 3B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ATRC trades at $58.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ATRC's P/E ratio is 1817.08. In terms of profitability, WST's ROE is +0.21%, compared to ATRC's ROE of +0.03%. Regarding short-term risk, WST is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for WST.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
WST vs BLFS Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas BLFS's P/E ratio is 37.49. In terms of profitability, WST's ROE is +0.21%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, WST is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for WST.Check BLFS's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
WST vs XRAY Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while XRAY trades at $9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas XRAY's P/E ratio is 6.62. In terms of profitability, WST's ROE is +0.21%, compared to XRAY's ROE of -0.09%. Regarding short-term risk, WST is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for WST.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
WST vs LMAT Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while LMAT trades at $80.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas LMAT's P/E ratio is 29.76. In terms of profitability, WST's ROE is +0.21%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, WST is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for WST.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
WST vs AZTA Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, AZTA has a market cap of 1.7B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while AZTA trades at $39.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas AZTA's P/E ratio is 93.33. In terms of profitability, WST's ROE is +0.21%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, WST is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for WST.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
WST vs KMTS Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, KMTS has a market cap of 1.7B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while KMTS trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas KMTS's P/E ratio is -10.86. In terms of profitability, WST's ROE is +0.21%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, WST is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for WST.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
WST vs STAA Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, STAA has a market cap of 1.3B. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while STAA trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas STAA's P/E ratio is 44.23. In terms of profitability, WST's ROE is +0.21%, compared to STAA's ROE of +0.00%. Regarding short-term risk, WST is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for WST.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
WST vs ATRI Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ATRI's P/E ratio is 64.50. In terms of profitability, WST's ROE is +0.21%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, WST is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRI's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
WST vs MMEDV Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas MMEDV's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.21%, compared to MMEDV's ROE of N/A. Regarding short-term risk, WST is more volatile compared to MMEDV. This indicates higher risk in terms of short-term price fluctuations for WST.Check MMEDV's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
WST vs ANGO Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ANGO has a market cap of 493.1M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ANGO trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ANGO's P/E ratio is -30.06. In terms of profitability, WST's ROE is +0.21%, compared to ANGO's ROE of -0.19%. Regarding short-term risk, WST is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for WST.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
WST vs EMBC Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, EMBC has a market cap of 350M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while EMBC trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas EMBC's P/E ratio is 2.38. In terms of profitability, WST's ROE is +0.21%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, WST is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for WST.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
WST vs SMTI Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, SMTI has a market cap of 289.9M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while SMTI trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas SMTI's P/E ratio is -525.83. In terms of profitability, WST's ROE is +0.21%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, WST is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for WST.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
WST vs OSUR Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, OSUR has a market cap of 237.9M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while OSUR trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas OSUR's P/E ratio is -5.00. In terms of profitability, WST's ROE is +0.21%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, WST is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for WST.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
WST vs UTMD Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, UTMD has a market cap of 230.4M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while UTMD trades at $72.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas UTMD's P/E ratio is 21.48. In terms of profitability, WST's ROE is +0.21%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, WST is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for WST.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
WST vs PDEX Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, PDEX has a market cap of 201M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while PDEX trades at $63.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas PDEX's P/E ratio is 17.21. In terms of profitability, WST's ROE is +0.21%, compared to PDEX's ROE of +0.26%. Regarding short-term risk, WST is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for WST.Check PDEX's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
WST vs NNNN Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, NNNN has a market cap of 169M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while NNNN trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas NNNN's P/E ratio is 25.67. In terms of profitability, WST's ROE is +0.21%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, WST is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for WST.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
WST vs KRMD Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, KRMD has a market cap of 141.7M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while KRMD trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas KRMD's P/E ratio is -77.12. In terms of profitability, WST's ROE is +0.21%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, WST is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for WST.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
WST vs STXS Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, STXS has a market cap of 111.2M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while STXS trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas STXS's P/E ratio is -6.53. In terms of profitability, WST's ROE is +0.21%, compared to STXS's ROE of -1.33%. Regarding short-term risk, WST is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for WST.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
WST vs AKYA Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas AKYA's P/E ratio is -1.34. In terms of profitability, WST's ROE is +0.21%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, WST is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for WST.Check AKYA's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
WST vs POCI Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, POCI has a market cap of 53.8M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while POCI trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas POCI's P/E ratio is -10.66. In terms of profitability, WST's ROE is +0.21%, compared to POCI's ROE of -0.24%. Regarding short-term risk, WST is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for WST.Check POCI's competition here
SkyAI, Inc. (NASDAQ: STSS)
WST vs STSS Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas STSS's P/E ratio is -0.02. In terms of profitability, WST's ROE is +0.21%, compared to STSS's ROE of -1.54%. Regarding short-term risk, WST is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
WST vs OMIC Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas OMIC's P/E ratio is -0.58. In terms of profitability, WST's ROE is +0.21%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, WST is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for WST.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
WST vs IGAP Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas IGAP's P/E ratio is -10.52. In terms of profitability, WST's ROE is +0.21%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, WST is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for WST.Check IGAP's competition here
Daxor Corporation (NASDAQ: DXR)
WST vs DXR Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, DXR has a market cap of 49.4M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while DXR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas DXR's P/E ratio is 6.88. In terms of profitability, WST's ROE is +0.21%, compared to DXR's ROE of +0.13%. Regarding short-term risk, WST is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for WST.Check DXR's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
WST vs HBIO Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, HBIO has a market cap of 38.2M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while HBIO trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas HBIO's P/E ratio is -23.31. In terms of profitability, WST's ROE is +0.21%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, WST is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for WST.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
WST vs NEPH Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, NEPH has a market cap of 30.6M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while NEPH trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas NEPH's P/E ratio is 46.92. In terms of profitability, WST's ROE is +0.21%, compared to NEPH's ROE of +0.17%. Regarding short-term risk, WST is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for WST.Check NEPH's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
WST vs SDC Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas SDC's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.21%, compared to SDC's ROE of -1.96%. Regarding short-term risk, WST is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for WST.Check SDC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
WST vs MLSS Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, MLSS has a market cap of 27.5M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while MLSS trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas MLSS's P/E ratio is -6.07. In terms of profitability, WST's ROE is +0.21%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, WST is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check MLSS's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
WST vs ZJYL Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ZJYL has a market cap of 26.1M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ZJYL trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ZJYL's P/E ratio is 22.78. In terms of profitability, WST's ROE is +0.21%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for WST.Check ZJYL's competition here
Invacare Corporation (NYSE: IVC)
WST vs IVC Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas IVC's P/E ratio is -0.79. In terms of profitability, WST's ROE is +0.21%, compared to IVC's ROE of -0.46%. Regarding short-term risk, WST is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for WST.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
WST vs RVP Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, RVP has a market cap of 16.9M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while RVP trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas RVP's P/E ratio is -4.69. In terms of profitability, WST's ROE is +0.21%, compared to RVP's ROE of -0.05%. Regarding short-term risk, WST is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for WST.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
WST vs BNGO Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, BNGO has a market cap of 13.5M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while BNGO trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas BNGO's P/E ratio is -0.38. In terms of profitability, WST's ROE is +0.21%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, WST is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for WST.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
WST vs FEMY Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, FEMY has a market cap of 11.6M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while FEMY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas FEMY's P/E ratio is -0.31. In terms of profitability, WST's ROE is +0.21%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, WST is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for WST.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
WST vs RGNT Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, RGNT has a market cap of 8.1M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while RGNT trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas RGNT's P/E ratio is -0.47. In terms of profitability, WST's ROE is +0.21%, compared to RGNT's ROE of N/A. Regarding short-term risk, WST is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for WST.Check RGNT's competition here
Lucyd, Inc (NASDAQ: LUCY)
WST vs LUCY Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, LUCY has a market cap of 7.2M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while LUCY trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas LUCY's P/E ratio is -0.64. In terms of profitability, WST's ROE is +0.21%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, WST is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for WST.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
WST vs NSTG Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas NSTG's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.21%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, WST is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for WST.Check NSTG's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
WST vs CUPR Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, CUPR has a market cap of 4.8M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while CUPR trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas CUPR's P/E ratio is -1.31. In terms of profitability, WST's ROE is +0.21%, compared to CUPR's ROE of -0.85%. Regarding short-term risk, WST is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for WST.Check CUPR's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
WST vs POAI Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas POAI's P/E ratio is -0.38. In terms of profitability, WST's ROE is +0.21%, compared to POAI's ROE of -21.19%. Regarding short-term risk, WST is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for WST.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
WST vs MHUA Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas MHUA's P/E ratio is 0.25. In terms of profitability, WST's ROE is +0.21%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, WST is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for WST.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
WST vs GMVD Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas GMVD's P/E ratio is -0.01. In terms of profitability, WST's ROE is +0.21%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, WST is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
WST vs GMVDW Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas GMVDW's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.21%, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, WST is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
WST vs NXGL Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while NXGL trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas NXGL's P/E ratio is -5.01. In terms of profitability, WST's ROE is +0.21%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, WST is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for WST.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
WST vs AVGR Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas AVGR's P/E ratio is -0.05. In terms of profitability, WST's ROE is +0.21%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, WST is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for WST.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
WST vs NXGLW Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, NXGLW has a market cap of 496.3K. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, WST's ROE is +0.21%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, WST is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for WST.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
WST vs LUCYW Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas LUCYW's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.21%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, WST is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for WST.Check LUCYW's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
WST vs HRC Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas HRC's P/E ratio is 41.92. In terms of profitability, WST's ROE is +0.21%, compared to HRC's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for WST.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
WST vs ALOG Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ALOG's P/E ratio is 40.93. In terms of profitability, WST's ROE is +0.21%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, WST is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for WST.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
WST vs ATRS Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas ATRS's P/E ratio is 14.95. In terms of profitability, WST's ROE is +0.21%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, WST is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRS's competition here
IntriCon Corporation (NASDAQ: IIN)
WST vs IIN Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas IIN's P/E ratio is 226.45. In terms of profitability, WST's ROE is +0.21%, compared to IIN's ROE of -0.00%. Regarding short-term risk, WST is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for WST.Check IIN's competition here
Apria, Inc. (NASDAQ: APR)
WST vs APR Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas APR's P/E ratio is 22.59. In terms of profitability, WST's ROE is +0.21%, compared to APR's ROE of +9.81%. Regarding short-term risk, WST is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for WST.Check APR's competition here
Invuity, Inc. (NASDAQ: IVTY)
WST vs IVTY Comparison November 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 27.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, WST is priced at $399.81 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 43.48, whereas IVTY's P/E ratio is -3.80. In terms of profitability, WST's ROE is +0.21%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, WST is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for WST.Check IVTY's competition here